YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a fresh round of high-conviction bets last week, adding heavily to Meta Platforms (NASDAQ:META) and Rocket Lab (NASDAQ:RKLB) while cutting exposure to several technolo…
Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of…
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. Continue Reading
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology…
Scribe Therapeutics Inc. Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering…
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up the summer months and head into the Labor Day long weekend holiday. All the major indices closed lower on Friday, but the markets enjoyed a positive week overall.…
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as…
[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next wee…
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes…
Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report.…
This article first appeared on GuruFocus. Scribe Therapeutics (NASDAQ:SCTX), a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alame…
(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. Most Read from Bloomberg Retina Chip Designe…
This article first appeared on GuruFocus. Scribe Therapeutics (SCTX), a gene-editing company backed by Eli Lilly (NYSE:LLY), raised $128.7 million after pricing an upsized initial public offering at the top of its expected range. The biote…
(RTTNews) - Scribe Therapeutics Inc. (SCTX), a clinical-stage biotechnology company, announced pricing of its upsized initial public offering of 8.58 million shares of its common stock at the high end of the range at a public offering pric…
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lif…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for…
This article first appeared on GuruFocus. Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial public offering. The Alameda, California-ba…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics, a biotechnology startup developing genetic medicines for cardiometabolic…